Nektar Pharmaceuticals and Bristol-Myers Squibb announced results for their experimental cancer drug, NKTR-214, pushing forward into late-stage trials testing the medicine against melanoma, renal cell carcinoma, and urothelial cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,